Delivery Order SPE2DB20D3303-SPE2DB25FA2HA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,176.37 to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injectors. This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 3, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the company's demonstrated...
- The Defense Logistics Agency awarded a $4,803.48 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract is a firm fixed price delivery order with an ultimate completion date of July 31, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting the contractor's established capability...
- The Defense Logistics Agency awarded a delivery order valued at $6,948.71 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of November 5, 2025. This non-competitive, firm fixed-price delivery order was issued on November 4, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA's Medical...
- The Defense Logistics Agency awarded a delivery order valued at $11,573.95 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors. This firm fixed-price delivery order, issued on September 12, 2025, with an ultimate completion date of September 15, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was competitively awarded without set-aside designation. AmerisourceBergen, a major...
- The Defense Logistics Agency awarded a $38,297.64 delivery order to AmerisourceBergen Drug Corp on December 18, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injectors. This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 19, 2025, with performance taking place at the vendor's Conshohocken, Pennsylvania headquarters. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $7,020.34 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for Repatha 140 mg/ml SureClick auto-injectors. The delivery order, which represents a child contract under a larger vehicle, has an ultimate completion date of October 23, 2025. This non-set-aside award reflects a competitive procurement process for pharmaceutical supplies supporting military and federal healthcare systems. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $1,757.77 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. This firm fixed price, non-set-aside contract was executed on August 21, 2025, with an ultimate completion date of August 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order issued under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a $15,882.49 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of December 22, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a $16,101.52 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector medication. This firm fixed-price, competitively awarded contract was issued on November 20, 2025, with an ultimate completion date of November 21, 2025. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical...
- The Defense Logistics Agency awarded a $41,766.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract, which is a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX, valued at $999,999,999.00 through December 2026), carries an ultimate completion date of August 22, 2025. This award was competitively granted with no...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2HADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,803.93 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injectors. This firm fixed price, non-competitive delivery order is scheduled for completion by August 8, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger federal pharmaceutical supply framework. This award is a child contract derived from AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical supply vendor, AmerisourceBergen leverages this prime vehicle to deliver comprehensive pharmaceutical products and medical supplies to support military and veteran healthcare systems globally. Repatha is a PCSK9 inhibitor used in cardiovascular disease management, reflecting the company's role in supplying specialty medications alongside brand-name drugs, generics, and medical devices across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.8k | 8/7/25 |